Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide


Published on

Renub Research has announced the addition of the "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” report to its offering

Click here to view the report details:

Contact Us

Andy Hill
Sr. Manager - Publisher Relation
Sales & Marketing Div.
Renub Research
Phone: +1-678-302-0700 (USA) , +91-120-4219-822, +91-120-254-5750 (India)

About US:

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

Published in: Business, Health & Medicine
  • Be the first to comment

  • Be the first to like this

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

  1. 1. Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide Renub Research Published: July, 2013 Copyright © 2013 Renub Research – All Rights Reserved From Data to Analysis Hepatitis C Market Research Report
  2. 2. Hepatitis C Market Overview Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end- stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in- class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care. Renub Research study titled “Hepatitis C Drug Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters. A. Hepatitis C Drugs Market & Forecast (Chapter 2) B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3) C. Hepatitis C Deals & Acquisitions (Chapter 4) D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5) E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6) F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7) Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3) 1. Pegasys 2. Pegintron 3. Incivek 4. Victrelis © Renub Research Page 2 of 12
  3. 3. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5) 1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical) 2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim) 3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb) 4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb) 5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences) 6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb) 7. BI-207127 (Company: Boerhinger Ingelheim) 8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories) 9. ABT-267 (Company: Abbott Laboratories) 10.ABT-072/333 (Company: Abbott Laboratories) 11.Alisporivir (Company: Novartis) Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6) 1. Mericitabine (RG-7128) (Company: Roche) 2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche) 3. GS-9256 (Company: Gilead Sciences) 4. GS-9451 (Company: Gilead Sciences) 5. MK-5172 (Company: Merck) 6. Sovaprevir (ACH-1625) (Company: Achillion) 7. IDX-320 (Company: Idenix) 8. MK-8742 (Company: Merck) 9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc) 10.IDX-719 (Company: Idenix) 11.PPI-668 (Company: Presidio Pharmaceuticals) 12.Setrobuvir (ANA-598) (Company: Roche) 13.VX-222 (Company: Vertex Pharmaceuticals) 14.GS-9669 (Company: Gilead Sciences) 15.GS-9190 (Tegobuvir) (Company: Gilead Sciences) 16.BMS-791325 (Company: Bristol-Myers Squibb)
  4. 4. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7) 1. Simeprevir (TMC 435) 2. Faldaprevir (BI 201335) (Boerhinger Ingelheim) 3. Asunaprevir (BMS-650032) 4. Sofosbuvir (PSI-7977 or GS-7977) 5. Daclatasvir (BMS-790052) 6. ABT-450/r (Ritonavir) 7. ABT-072/333 8. Alisporivir 9. Mericitabine (RG-7128) 10.Danoprevir (RG7227) 11.GS-9256 12.Setrobuvir (ANA-598) 13.VX-222 14.GS-9190 (Tegobuvir) 15.BMS-791325 Data Sources This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephone interviews with industry experts. Secondary sources information and data has been collected from various printable and non- printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases. © Renub Research Page 4 of 12
  5. 5. Table of Contents 1. Executive Summary 2. Hepatitis C Drugs – Market & Forecast 3. Hepatitis C – Approved Drugs Sales & Forecast 3.1 Pegasys Sales and Forecast 3.2 Pegintron Sales and Forecast 3.3 Incivek Sales and Forecast 3.4 Victrelis Sales and Forecast 4. Hepatitis C – Deals & Acquisitions 5. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) 5.1 Simeprevir (TMC 435) (Company: Janssen Pharmaceutical) 5.1.1 Phase I 5.1.2 Phase II 5.1.3 Phase III 5.2 Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim) 5.2.1 Phase I 5.2.2 Phase II 5.2.3 Phase III 5.3 Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb) 5.3.1 Phase I 5.3.2 Phase II 5.3.3 Phase III 5.4 Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences) © Renub Research Page 5 of 12
  6. 6. 5.4.1 Phase II 5.4.2 Phase III 5.5 Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb) 5.5.1 Phase II 5.5.2 Phase III 5.6 BI-207127 (Company: Boerhinger Ingelheim) 5.6.1 Phase I 5.6.2 Phase II 5.6.3 Phase III 5.7 PEG-Interferon Lambda (Company: Bristol-Myers Squibb) 5.7.1 Phase I 5.7.2 Phase III 5.8 ABT-450/r (Ritonavir) (Company: Abbott Laboratories) 5.8.1 Phase I 5.8.2 Phase II 5.8.3 Phase III 5.9 ABT-267 (Company: Abbott Laboratories) 5.9.1 Phase II 5.9.2 Phase III 5.10 ABT-072/333 (Company: Abbott Laboratories) 5.10.1 Phase I 5.10.2 Phase II 5.10.3 Phase III 5.11 Alisporivir (Company: Novartis) 5.11.1 Phase II 5.11.2 Phase III © Renub Research Page 6 of 12
  7. 7. 6. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) 6.1 Mericitabine (RG-7128) (Company: Roche) 6.1.1 Phase II 6.2 Danoprevir/r (Ritonavir) (RG7227) (Company: Roche) 6.2.1 Phase I 6.2.2 Phase II 6.3 GS-9256 (Company: Gilead Sciences) 6.3.1 Phase II 6.4 GS-9451 (Company: Gilead Sciences) 6.4.1 Phase II 6.5 MK-5172 (Company: Merck) 6.5.1 Phase I 6.5.2 Phase II 6.6 Sovaprevir (ACH-1625) (Company: Achillion) 6.6.1 Phase II 6.7 IDX-320 (Company: Idenix) 6.7.1 Phase I 6.8 MK-8742 (Company: Merck) 6.8.1 Phase I 6.8.2 Phase II 6.9 ACH-3102 (Company: Achillion Pharmaceuticals, Inc) 6.9.1 Phase I 6.9.2 Phase II © Renub Research Page 7 of 12
  8. 8. 6.10 IDX-719 (Company: Idenix) 6.10.1 Phase I 6.10.2 Phase II 6.11 PPI-668 (Company: Presidio Pharmaceuticals) 6.11.1 Phase I 6.12 Setrobuvir (ANA-598) (Company: Roche) 6.12.1 Phase I 6.12.2 Phase II 6.13 VX-222 (Company: Vertex Pharmaceuticals) 6.13.1 Phase I 6.13.2 Phase II 6.14 GS-9669 (Company: Gilead Sciences ) 6.14.1 Phase I 6.14.2 Phase II 6.15 GS-9190 (Tegobuvir) (Company: Gilead Sciences) 6.15.1 Phase II 6.16 BMS-791325 (Company: Bristol-Myers Squibb) 6.16.1 Phase II 7. Hepatitis C - Pipeline Drugs Sales Forecast 7.1 Simeprevir (TMC 435) Sales Forecast 7.2 Faldaprevir (BI 201335) (Boerhinger Ingelheim) Sales Forecast 7.3 Asunaprevir (BMS-650032) Sales Forecast 7.4 Sofosbuvir (PSI-7977 or GS-7977) Sales Forecast 7.5 Daclatasvir (BMS-790052) Sales Forecast © Renub Research Page 8 of 12
  9. 9. 7.6 ABT-450/r (Ritonavir) Sales Forecast 7.7 ABT-072/333 Sales Forecast 7.8 Alisporivir Sales Forecast 7.9 Mericitabine (RG-7128) Sales Forecast 7.10 Danoprevir (RG7227) Sales Forecast 7.11 GS-9256 Sales Forecast 7.12 Setrobuvir (ANA-598) Sales Forecast 7.13 VX-222 Sales Forecast 7.14 GS-9190 (Tegobuvir) Sales Forecast 7.15 BMS-791325 Sales Forecast © Renub Research Page 9 of 12
  10. 10. Order Form Scan and e-mail this page to, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780 Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to Format Report Title: Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide Single User (Email from Publisher) Hard Copy (Mail Delivery) CD – Rom (Mail Delivery) Global Site License (Multiple User License) US$ 1,290 US$ 1,440 US$ 1,390 US$ 2,090 For ordering this report: Three easy ways to place your order: 1) Order online by Credit Card (Visa, MasterCard, etc.): c-pipeline-drugs-sales-forecast---worldwide-118 2) Order by Wire Transfer: To pay by Wire Transfer, please, fill in your contact details in the form below: © Renub Research Page 10 of 12
  11. 11. Bank Details Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi – 110001 India Contact Information First Name: Last Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message: © Renub Research Page 11 of 12
  12. 12. 3) Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research 1st floor, C-86, Sector -10, Noida - 201301 Uttar Pradesh India Phone: +91-120-421-9822, 424-9780 For free Sample copy report or to view any of our sample work please contact us at or call +91-120-421-9822 (India), +1-678-302-0700 (USA) Follow Us Facebook: LinkedIn: Twitter: © Renub Research Page 12 of 12